We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · November 04, 2019

Real-World Effectiveness and Tolerability of Pazopanib for mRCC in Latin America

Advances in Therapy


Additional Info

Advances in Therapy
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America
Adv Ther 2019 Oct 19;[EPub Ahead of Print], D Queiroz Muniz, B Ratto, H Yang, J Zhao, M Jenkins, J Signorovitch, L Dezzani, P Salman, M Lema Medina, D Lopera, G Lerzo, C Del Castillo, M Chacon, A Martin, S Campos-Gomez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading